Zura Bio Ltd (ZURA) - Dilution Analysis

10-Q filing | 95.0M shares outstanding

10-K filing | 94.2M shares outstanding

8-K filing: Zura Bio Limited issued 8,657,402 Class A ordinary shares to Athanor Capital in connection with the termination of certain letter agreements.

10-Q filing | 61.9M shares outstanding

8-K filing: Zura Bio Limited entered into share surrender and warrant agreements with Venrock Healthcare Capital Partners and AI Biotechnology, LLC, involving the surrender of 6.5 million Class A ordinary shares for no consideration and the issuance of warrants to purchase 6.5 million Ordinary Shares.

10-K filing | 65.3M shares outstanding

10-Q filing | 65.3M shares outstanding

S-3/A filing: ZURA BIO LIMITED is offering Class A ordinary shares, preferred shares and debt securities up to $300,000,000 in the aggregate, from time to time. Selling shareholder may offer and sell up to 525,000 Class A Ordinary Shares.

S-3/A filing: Zura Bio Limited files an S-3/A to offer up to $300,000,000 in Class A ordinary shares, preferred shares, and debt securities, with a secondary offering of 525,000 Class A Ordinary Shares by a selling shareholder.

POS AM filing: The filing discusses the consummation of a business combination and a private placement of Class A Ordinary Shares and pre-funded warrants in April 2024.

POS AM filing: This prospectus relates to the offering of Class A Ordinary Shares by Selling Securityholders using a shelf registration process.

S-3 filing: Zura Bio Limited is filing an S-3 to offer and sell up to $300,000,000 in the aggregate of Class A ordinary shares, preferred shares, debt securities, warrants and/or units.

8-K filing: Zura Bio Limited entered into a share surrender and warrant agreement with entities affiliated with Venrock Healthcare Capital Partners, involving the surrender of 4,000,000 Class A ordinary shares for no consideration and the issuance of warrants to purchase 4,000,000 Ordinary Shares.

10-Q filing | 63.7M shares outstanding

8-K filing: Zura Bio Limited completed its exchange offer relating to its outstanding public and private placement warrants, and entered into a warrant amendment to mandatorily exchange remaining IPO warrants for Class A ordinary shares at a ratio of 0.27 shares per warrant.

8-K filing: Zura Bio Limited completed an exchange offer for its outstanding public and private placement warrants, issuing 0.30 Class A ordinary shares for each tendered warrant, and expects to amend the warrant agreement to exchange remaining untendered warrants for 0.27 Class A ordinary shares each.

POS AM filing: This is a POS AM filing for JATT Acquisition Corp (now Zura Bio Limited). It includes information about ordinary shares, warrants, and a share issuance to Eli Lilly and Company.

10-Q filing | 46.9M shares outstanding

8-K filing: Zura Bio Limited completed a private placement on April 22, 2024, issuing 18,732,301 Class A Ordinary Shares and pre-funded warrants to purchase 16,102,348 Ordinary Shares to investors, and 1,357,827 Ordinary Shares to insiders, for gross proceeds of approximately $112.5 million. ($62.46M proceeds)

10-K filing | 43.6M shares outstanding

10-Q filing | 46.9M shares outstanding

S-1/A filing: This S-1/A filing relates to the offering price determination for Class A Ordinary Shares underlying Public Warrants and Private Placement Warrants, with an exercise price of $11.50 per share. It also mentions the market price of Zura's ordinary shares and public warrants as of August 22, 2023.

S-1/A filing: This S-1/A filing relates to the offering of Class A Ordinary Shares underlying Public Warrants and Private Placement Warrants, as well as shares issued to Lilly and FPA Investors.

10-Q filing | 43.1M shares outstanding

S-1/A filing: This is an S-1/A filing regarding the offering price of Class A Ordinary Shares underlying Public and Private Placement Warrants, with an exercise price of $11.50 per share. As of August 9, 2023, the closing sale price of the Class A Ordinary Shares was $6.70 per share.

S-1/A filing: This S-1/A filing relates to the offering price of Class A Ordinary Shares underlying Public and Private Placement Warrants, with an exercise price of $11.50 per share. As of July 21, 2023, there were 35 holders of record of the Class A Ordinary Shares and 6 holders of record of the Public Warrants.

S-1 filing: This is an S-1 filing related to JATT Acquisition Corp, covering topics such as the determination of offering price for Class A Ordinary Shares underlying warrants and information on the market price and dividends of the company's shares.

8-K filing: Zura Bio Limited completed a second closing on June 5, 2023, issuing 15,073,530 Class A ordinary shares (including shares issuable upon exercise of pre-funded warrants) for approximately $64 million pursuant to subscription agreements. ($80.0M proceeds)

10-Q filing | 27.1M shares outstanding

8-K filing: The company issued a total of 6,801,633 Class A Ordinary Shares to Athanor Master Fund, LP and Athanor International Master Fund, LP, with 3,000,000 shares sold at $10 per share for $30,000,000, 1,301,633 shares sold at $10 per share for $13,016,330, and an additional 2,500,000 shares issued for no additional monetary consideration. ($43.02M proceeds)

10-K filing | 3.5M shares outstanding

8-K filing: On March 13, 2023, JATT entered into a Subscription Agreement with an unaffiliated accredited investor for 9,950 Class A ordinary shares at $10.00 per share, for an aggregate subscription price of $99,500, with the closing contingent on the Business Combination. ($0.1M proceeds)

8-K filing: JATT Acquisition Corp entered into Amendment No. 2 to Forward Purchase Agreement with Athanor Master Fund, LP, and Athanor International Master Fund, LP, where the Purchasers agreed to purchase up to 1,500,000 shares of JATT's Class A ordinary shares from the Company for up to $15,000,000 and will be issued an additional 2,500,000 Class A Shares upon the closing of the business combination with Zura Bio Limited. ($15.0M proceeds)

8-K filing: JATT Acquisition Corp issued 550,000 Class A ordinary shares to Eli Lilly and Company in a private placement transaction as partial consideration for Lilly entering into a License Agreement with Z33 Bio Inc.

10-Q filing | 3.5M shares outstanding

10-Q filing | 3.5M shares outstanding

8-K filing: JATT Acquisition Corp entered into a Business Combination Agreement with Zura Bio Limited, involving PIPE and FPA investments. The PIPE Investor committed to purchase 2,000,000 shares of JATT Class A Shares at $10.00 per share for $20,000,000, and the FPA Investors committed to purchase 3,000,000 JATT Class A Shares at $10.00 per share for $30,000,000. ($50.0M proceeds)

10-Q filing | 3.5M shares outstanding

10-K filing | 3.5M shares outstanding

8-K filing: JATT Acquisition Corp amended its Forward Purchase Agreements with Athanor Master Fund LP and Athanor International Master Fund, LP, involving the sale of 3,000,000 forward purchase shares at $10.00 per share, a redemption backstop of $15 million, and bridge financing of $30 million to the target merger company. ($30.0M proceeds)

10-Q filing | 3.5M shares outstanding

10-Q filing | 4.3M shares outstanding

10-Q filing | 3.5M shares outstanding

8-K filing: JATT Acquisition Corp entered into Forward Purchase Agreements with Athanor Master Fund LP and Athanor International Master Fund, LP for the purchase of 7,500,000 forward purchase shares at $10.00 per share, totaling $75,000,000 in the aggregate, contingent upon the company's initial business combination closing. ($75.0M proceeds)

8-K filing: JATT Acquisition Corp consummated its initial public offering of 12,000,000 units at $10.00 per Unit, generating gross proceeds of $120,000,000; simultaneously, the Sponsor purchased 5,370,000 private warrants at $1.00 per warrant, generating total proceeds of $5,370,000; furthermore, the Company consummated the sale of an additional 1,800,000 Units, and the sale of an additional 540,000 Private Placement Warrants, as described below, each at $1.00 per warrant, generating total gross proceeds of $18,540,000; Upon the closing of the Over-allotment Option, the Sponsor purchased an additional 540,000 Private Placement Warrants for an aggregate purchase price of $540,000. ($5.91M proceeds)

8-K filing: JATT Acquisition Corp consummated its IPO of 12,000,000 units at $10.00 per unit, generating gross proceeds of $120,000,000, and also consummated a private placement in which the Sponsor purchased 5,370,000 private warrants at $1.00 per warrant, generating total proceeds of $5,370,000. ($144.45M proceeds)

S-1/A filing: This S-1/A filing relates to an initial public offering of units, each consisting of one Class A ordinary share and one-half of one redeemable warrant, and a concurrent private placement of warrants to the sponsor.

S-1 filing: This S-1 filing outlines the initial public offering of units, each comprising one Class A ordinary share and one-half of a warrant, along with a concurrent private placement of warrants to the sponsor, JATT Ventures, L.P.